Ursolic acid-enriched kudingcha extract enhances the antitumor activity of bacteria-mediated cancer immunotherapy

BMC Complement Med Ther. 2022 May 4;22(1):123. doi: 10.1186/s12906-022-03612-2.

Abstract

Background: Bacteria-mediated cancer immunotherapy (BCI) robustly stimulates the immune system and represses angiogenesis, but tumor recurrence and metastasis commonly occur after BCI. The natural product Ilex kudingcha C. J Tseng enriched with ursolic acid has anti-cancer activity and could potentially augment the therapeutic effects of BCI. The objective of the present study was to determine potential additive effects of these modalities.

Methods: We investigated the anti-cancer activity of KDCE (Kudingcha extract) combined with S.t△ppGpp in the mice colon cancer models.

Results: In the present study, KDCE combined with S.t△ppGpp BCI improved antitumor therapeutic efficacy compared to S.t△ppGpp or KDCE alone. KDCE did not prolong bacterial tumor-colonizing time, but enhanced the antiangiogenic effect of S.t△ppGpp by downregulatingVEGFR2. We speculated that KDCE-induced VEGFR2 downregulation is associated with FAK/MMP9/STAT3 axis but not AKT or ERK.

Conclusions: Ursolic acid-enriched KDCE enhances the antitumor activity of BCI, which could be mediated by VEGFR2 downregulation and subsequent suppression of angiogenesis. Therefore, combination therapy with S.t△ppGpp and KDCE is a potential cancer therapeutic strategy.

Keywords: Antiangiogenesis; BCI; Ursolic acid-enriched KDCE; VEGFR2.

MeSH terms

  • Animals
  • Bacteria
  • Disease Models, Animal
  • Ilex*
  • Immunotherapy
  • Mice
  • Neoplasms*
  • Plant Extracts / pharmacology
  • Triterpenes
  • Ursolic Acid

Substances

  • Plant Extracts
  • Triterpenes